BBOT
NASDAQBridgeBio Oncology Therapeutics Inc.
News25/Ratings9
Price$9.37+0.27 (+3.02%)
2026-05-212026-08-25
News · 26 weeks59-43%
2026-03-012026-08-23
Mix2190d
- Insider12(57%)
- SEC Filings4(19%)
- Other3(14%)
- Analyst2(10%)
Latest news
25 items- PRBridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded inducement grants on August 10, 2026 under BBOT’s 2025 Inducement Plan as a material inducement to the employment of two individuals hired by BBOT in July 2026. The employees received non-qualified stock options to purchase an aggregate 65,350 shares of BBOT common stock, par value $0.0001 per share, with an exercise price of $9.28 per share, the closing price of BBOT’s common stock as reported by Nasdaq on the effective date of the grant, which will vest 1/4 o
- SECSEC Form 10-Q filed by BridgeBio Oncology Therapeutics Inc.10-Q - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)
- SECBridgeBio Oncology Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)
- PRBBOT Reports Second Quarter 2026 Financial Results and Update on Corporate ProgressContinued to advance monotherapy and combination cohorts for all clinical programsInitiated dosing of BBO-11818 in combination with cetuximab and after the end of the quarter, initiated dosing of BBO-11818 in combination with BBO-10203Presented preclinical data at AACR highlighting the potency and activity of BBO-11818 in KRAS mutant tumor models and the efficacy of BBO-10203 in combination with tucatinib and trastuzumab in HER2amp models Cash runway expected to fund operations into 2028 SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies,
- ANALYSTAnalyst initiated coverage on BridgeBio Oncology Therapeutics with a new price targetAnalyst initiated coverage of BridgeBio Oncology Therapeutics with a rating of Overweight and set a new price target of $27.00
- INSIDERCOO & Principal Financial Ofcr Elmelech Idan covered exercise/tax liability with 343 shares, decreasing direct ownership by 2% to 14,495 units (SEC Form 4) (for withholding tax)4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
- INSIDERPrincipal Accounting Officer Cobo Marc covered exercise/tax liability with 125 shares, decreasing direct ownership by 2% to 5,306 units (SEC Form 4) (withholding tax)4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
- INSIDERPresident and CEO Beltran Pedro covered exercise/tax liability with 1,047 shares, decreasing direct ownership by 2% to 44,576 units (SEC Form 4) (for withholding tax)4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
- INSIDERChief Med & Dev Officer Ben Yong covered exercise/tax liability with 1,047 shares, decreasing direct ownership by 2% to 44,576 units (SEC Form 4) (tax withholding)4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by BridgeBio Oncology Therapeutics Inc.SCHEDULE 13D/A - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Subject)
- INSIDERDirector Chen Bihua disposed of 4,528,186 shares and acquired 4,528,186 shares (SEC Form 4)4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
- SECSEC Form 424B3 filed by BridgeBio Oncology Therapeutics Inc.424B3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)
- SECSEC Form 8-K filed by BridgeBio Oncology Therapeutics Inc.8-K - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)
- ANALYSTOppenheimer resumed coverage on BridgeBio Oncology Therapeutics with a new price targetOppenheimer resumed coverage of BridgeBio Oncology Therapeutics with a rating of Outperform and set a new price target of $22.00
- INSIDERSEC Form 4 filed by Director Tipirneni Praveen P.4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
- INSIDERSEC Form 4 filed by Director Mccormick Frank4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
- INSIDERSEC Form 4 filed by Director Lebowitz Peter F4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
- INSIDERSEC Form 4 filed by Director Kelleher Raymond J.4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
- INSIDERSEC Form 4 filed by Director Chen Bihua4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
- INSIDERSEC Form 4 filed by Director Bauer Jake4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
- INSIDERSEC Form 4 filed by Director Kumar Neil4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
- SECSEC Form 424B3 filed by BridgeBio Oncology Therapeutics Inc.424B3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)
- SECSEC Form 10-Q filed by BridgeBio Oncology Therapeutics Inc.10-Q - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)
- SECBridgeBio Oncology Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)
- PRBBOT Reports First Quarter 2026 Financial Results and Update on Corporate ProgressAnnounced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programsAnnounced publication in Cancer Discovery highlighting preclinical data demonstrating BBO-11818 is a potent and selective pan-KRAS inhibitorClinical readouts expected in the second half of 2026 across all three programsCash runway expected to fund operations into 2028 SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the first quarter ended March 31, 2026, and provided a business update, including
BBOT FAQ
6 questionsWhere does BBOT stock trade?
BridgeBio Oncology Therapeutics Inc. (BBOT) is listed on NASDAQ.What sector and industry is BBOT in?
BridgeBio Oncology Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did BridgeBio Oncology Therapeutics Inc. go public?
BridgeBio Oncology Therapeutics Inc. (BBOT) completed its IPO in 2024.What are analysts saying about BBOT?
BridgeBio Oncology Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Analyst: Overweight with a $2700.00 price target on 2026-07-08. Recent price targets range from $2000.00 to $2700.00.What companies are similar to BBOT?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare BBOT side-by-side with any of them on Quantisnow.How can I track BBOT on Quantisnow?
Quantisnow aggregates BridgeBio Oncology Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BBOT to receive live email and push alerts on every new disclosure.